RE: Anticipated StingRay outcome2 Jun 2026 08:34
Comrade Paternostpauper speaks with exemplary ideological alignment.
This morning's communiqué from the Ministry of Portfolio Truth confirms that Stingray has achieved a highly successful non-progression. The asset was found insufficiently advanced for licensing, thereby proving the effectiveness of the licensing criteria. Had the asset met the criteria it would have progressed; by not progressing, it has demonstrated that the criteria are working perfectly.
The Party's Three Principles of Modern Drug Development are now clear:
Failure is Success
The technology did not fail to qualify. Rather, qualification succeeded in identifying the technology. The evaluation was completed ahead of schedule and under budget, demonstrating that time itself now obeys management guidance.
Reduction is Expansion
Every asset removed from the pipeline increases the value of those remaining. A smaller portfolio is therefore a larger opportunity. By owning fewer programmes, we possess more focus. By possessing more focus, we possess more value.
Non-Licensing is Monetisation
The greatest commercial triumph is not to acquire an asset at all. Through advanced strategic abstinence, ValiRx has transformed a decision not to license into a potential 1.5x return on expenditure. We have entered the age of revenue by non-ownership.
Citizens should therefore understand that Stingray has not been terminated. It has been liberated from participation in the portfolio while remaining fully available to contribute to future upside.
As the Ministry reminds us:
"Every asset is equal, but some assets are more monetisable than others."
GLA. Continuous portfolio rectification remains doubleplusgood.
Sign In
Follow the stocks
